Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?

Annals of Neurology

Volumn 58, Issue 1, 2005, Pages 139-142

  Schoonenboom, Niki S ^a,b   Mulder, Cees ^b   Van Kamp, Gerard J ^b   Mehta, Sangita P ^c   Scheltens, Philip ^a   Blankenstein, Marinus A ^b   Mehta, Pankaj D ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 21844454462     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20508     Document Type: Article

References (20)

1. Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem 1996;271:31894-31902.
2. Kumar-Singh S, De Jonghe C, Cruts M, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet 2000;9:2589-2598.
3. Wiltfang J, Esselmann H, Bibl M, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.
4. Mehta PD, Pirtttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
5. Schoonenboom NS, Pijnenburg YA, Mulder C, et al. Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580-1584.
6. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46;860-866.
7. Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 2004;25:273-281.
8. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
9. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal antiinflammatory drugs lower Abeta(42) and change presenilin 1 conformation. Nat Med 2004;10:1065-1066.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Potempska A, Mack K, Mehta PD, et al. Quantitation of subfemtomole amounts of Alzheimer amyloid beta peptides. Amyloid. 1999;16:14-21.
13. Mehra PD, Mehta SP, Fedor B, et al. Plasma amyloid beta proteinl-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett 2003;342:155-158.
14. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-720.
15. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
16. Lewczuk P, Esselmann H, Meyer M, et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003;17:1291-1296.
17. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beral-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
18. Wiltfang J, Esselmann H, Cupers P, et al. Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 2001;276:42645-42657.
19. Pype S, Moechars D, Dillen L, Mercken M. Characrerization of amyloid β peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem 2003;84:602-609.
20. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.